A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

Name: A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
Published: 2026
License: Public Domain

TwoStep Therapeutics, Inc. · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

gastric-cancer nsclc ovarian-cancer

nsclc (non-small cell lung cancer), hnscc, endometrial, ovarian cancer, esophageal cancer, head & neck cancer, gastric cancer (gc), endometrial cancer, ts-104, twostep, nsclc, gastric cancer

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 858509
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.